On November 3, Shijiazhuang No. 4 Pharmaceutical Group's azithromycin dispersible tablets (0.25g) received the "Approval Notice for Supplementary Drug Application" from the National Medical Products Administration, passing the consistency evaluation of generic drug quality and efficacy. This is another new achievement for the group in the field of oral anti-infective preparations.It is understood that azithromycin dispersible tablets are a macrolide antibiotic, mainly used for respiratory tract infections, skin and soft tissue infections and other diseases caused by susceptible strains.Leveraging its integrated "API + formulation" industrial layout, the group has established a significant differentiated competitive advantage in its azithromycin product chain. Previously, the company's azithromycin dry suspension, azithromycin tablets, and azithromycin for injection (lyophilized powder for injection) dosage forms had passed or were deemed to have passed the consistency evaluation. With the approval of the azithromycin dispersible tablets, the group has not only further enriched its azithromycin formulation product chain but also gained a more prominent market advantage in subsequent hospital procurement access, primary healthcare market coverage, and retail channel sales.To date, the group has accumulated 208 varieties and 278 specifications of products that have passed or are deemed to have passed the consistency evaluation of generic drug quality and efficacy, and the product structure continues to be optimized and the product pipeline is becoming increasingly rich.

Source: https://mp.weixin.qq.com/s?__biz=MzA4MDk2MzA1NQ==&mid=2247507023&idx=1&sn=995ad50ea7f869290a4cf77f6a8afb97&chksm=9e8c96e2ff74e794f80c36cca0807b75d151bf2dde7b421cbeb1cd9f9cf33b319fa6e3aff7af&scene=126&sessionid=0#rd